News & Events
Published On: 2/22/2021
TARGET-NASH Real-World Study Reveals Two Thirds Of Patients With NAFLD Had No Record Of Liver Biopsy
DURHAM, N.C., Feb. 22, 2021 /PRNewswire/ -- Target RWE, a leading real-world evidence (RWE) solutions company for the pharmaceutical and biotech industries, announced newest data from its ongoing nonalcoholic steatohepatitis (NASH) observational study, published in Hepatology Communications (https://doi.org/10.1002/hep4.1689).
The TARGET-NASH study, Patient Determinants for Histologic Diagnosis of Nonalcoholic Fatty Liver Disease in the Real World: A TARGET-NASH Study, aimed to determine patient characteristics that are predictive of having a diagnosis by biopsy versus a diagnosis using clinical criteria.
Analyzing 3,474 adult participants with nonalcoholic fatty liver disease (NAFLD) managed in usual clinical practice from August 2016 to March 2019, the study found 67% of the cohort had not had a liver biopsy. Predictive factors of having a diagnosis by biopsy included White race, female sex, diabetes, and elevated alanine aminotransferase (ALT). Overall, median age was 59 years, 59% were female, 75% White, and 66% obese. The most common comorbid conditions included cardiovascular disease (19%), osteoarthritis (10%), and mental health diagnoses or depression (49%). Of note, patients who had progressed to cirrhosis caused by NAFLD were 1.67 times more likely to be depressed than patients with nonalcoholic fatty liver, a less severe form of NAFLD.
"The data illustrates differences in the characteristics of patients who get a liver biopsy and those that don't. There may be inherent biases in who has a liver biopsy," said A. Sidney Barritt IV, MD, MSCR, Associate Professor of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, and lead author. "It is critical to better understand the source of the histological diagnosis of NAFLD/NASH as the FDA inches closer to medication approval and patients could be treated based on non-invasive clinical criteria."
"Significantly, 766 patients were diagnosed based on clinical criteria which highlights the need to utilize pragmatic diagnostic criteria for NASH," said Arun Sanyal, MD, Professor, Department of Internal Medicine, Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, and senior author. "As new interventions become available, the need for better systematic methods for diagnosis other than liver biopsy will become necessary more than ever."
The TARGET-NASH dataset provides a baseline and measures the impact of current practice guidelines, management, and new therapies utilized for patients with medical co-morbidities, hepatic, cardiovascular, and/or other endocrine-associated outcomes.
TARGET-NASH is a longitudinal study of adult and pediatric participants with NAFLD and/or NASH in usual clinical practice. Target RWE's network of NASH sites includes 65 community and academic centers in the U.S. and Europe, enrolling more than 5,700 participants to date. Three years of retrospective data is obtained at enrollment and patients are then followed prospectively for a minimum of 5 years, including the collection of patient-reported outcome measures and biospecimen samples.
About Target RWE
Target RWE is a leading health evidence solutions company that generates innovative real-world evidence (RWE) and provides scientific intelligence tools and solutions for pharmaceutical, biotechnology, and other healthcare partners. Specifically designed to address the complexities of the natural history of disease, the drug development process and treatments in real-world settings, Target RWE builds regulatory-grade clinical data sets and applies state of the science epidemiologic methods to produce RWE about patients with specific conditions, symptoms, and therapies used in usual clinical practice.
Target RWE's regulatory-grade data sets and evidence, modern epidemiological methods, and sound scientific principles rendered as software can be utilized to better health outcomes, inform patient health guidelines, and improve overall quality of care. For more information, visit www.targetrwe.com.
984.234.0268 ext 205
07/22/2021Target RWE HBV Research on Antiviral Treatments, Characteristics, and Clinical Outcomes Published in Digestive Diseases and Sciences
06/29/2021Liver International Publishes Hepatocellular Carcinoma RWE Review
06/22/2021Target RWE Study Shows Significant Differences in Medication Use Among Older Patients with IBD Compared to Younger Patients
06/15/2021TARGET-NASH Study Finds Statins Underutilized in Patients with NAFLD and At-Risk of Heart Disease
05/25/2021Target RWE COVID-19 Data: Real-World Evidence Analysis Shows 3.6% of COVID-19 Hospitalized Patients Discharged Alive Required Readmission